a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:297.

9. The antigen-binding molecule according to any one of claims **1** to **6**, wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:289; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:299.

10. An antigen-binding molecule, optionally isolated, comprising (i) an antigen-binding molecule according to any one of claims **1** to **9**, and (ii) an antigen-binding molecule capable of binding to an antigen other than VISTA.

11. A chimeric antigen receptor (CAR) comprising an antigen-binding molecule according to any one of claims **1** to **10**.

12. A nucleic acid, or a plurality of nucleic acids, optionally isolated, encoding an antigen-binding molecule according to any one of claims **1** to **10** or a CAR according to claim **11**.

13. An expression vector, or a plurality of expression vectors, comprising a nucleic acid or a plurality of nucleic acids according to claim **12**.

14. A cell comprising an antigen-binding molecule according to any one of claims **1** to **10**, a CAR according to claim **11**, a nucleic acid or a plurality of nucleic acids according to claim **12**, or an expression vector or a plurality of expression vectors according to claim **13**.

15. A method comprising culturing a cell comprising a nucleic acid or a plurality of nucleic acids according to claim **12**, or an expression vector or a plurality of expression vectors according to claim **13**, under conditions suitable for expression of the antigen-binding molecule or CAR from the nucleic acid(s) or expression vector(s).

16. A composition comprising an antigen-binding molecule according to any one of claims **1** to **10**, a CAR according to claim **11**, a nucleic acid or a plurality of nucleic acids according to claim **12**, an expression vector or a plurality of expression vectors according to claim **13**, or a cell according to claim **14**.

17. The composition according to claim **16**, additionally comprising an agent capable of inhibiting signalling mediated by an immune checkpoint molecule other than VISTA, optionally wherein the immune checkpoint molecule other than VISTA is selected from PD-1, CTLA-4, LAG-3, TIM-3, TIGIT and BTLA.

18. An antigen-binding molecule according to any one of claims **1** to **10**, a CAR according to claim **11**, a nucleic acid or a plurality of nucleic acids according to claim **12**, an expression vector or a plurality of expression vectors according to claim **13**, a cell according to claim **14**, or a composition according to claim **16** or claim **17** for use in a method of medical treatment or prophylaxis.

19. An antigen-binding molecule according to any one of claims **1** to **10**, a CAR according to claim **11**, a nucleic acid or a plurality of nucleic acids according to claim **12**, an expression vector or a plurality of expression vectors according to claim **13**, a cell according to claim **14**, or a composition according to claim **16** or claim **17**, for use in a method of treatment or prevention of a cancer or an infectious disease.

20. Use of an antigen-binding molecule according to any one of claims **1** to **10**, a CAR according to claim **11**, a nucleic acid or a plurality of nucleic acids according to claim **12**, an expression vector or a plurality of expression vectors according to claim **13**, a cell according to claim **14**, or a composition according to claim **16** or claim **17**, in the manufacture of a medicament for use in a method of treatment or prevention of a cancer or an infectious disease.

21. A method of treating or preventing a cancer or an infectious disease, comprising administering to a subject a therapeutically or prophylactically effective amount of an antigen-binding molecule according to any one of claims **1** to **10**, a CAR according to claim **11**, a nucleic acid or a plurality of nucleic acids according to claim **12**, an expression vector or a plurality of expression vectors according to claim **13**, a cell according to claim **14**, or a composition according to claim **16** or claim **17**.

22. The antigen-binding molecule, CAR, nucleic acid or plurality of nucleic acids, expression vector or plurality of expression vectors, cell or composition for use according to claim **19**, the use according to claim **20** or the method according to claim **21**, wherein the cancer is selected from: a cancer comprising cells expressing VISTA, a cancer comprising infiltration of cells expressing VISTA, a cancer comprising cancer cells expressing VISTA, a hematological cancer, leukemia, acute myeloid leukemia, lymphoma, B cell lymphoma, T cell lymphoma, multiple myeloma, mesothelioma, a solid tumor, lung cancer, non-small cell lung carcinoma, gastric cancer, gastric carcinoma, colorectal cancer, colorectal carcinoma, colorectal adenocarcinoma, uterine cancer, uterine corpus endometrial carcinoma, breast cancer, triple negative breast invasive carcinoma, liver cancer, hepatocellular carcinoma, pancreatic cancer, pancreatic ductal adenocarcinoma, thyroid cancer, thymoma, skin cancer, melanoma, cutaneous melanoma, kidney cancer, renal cell carcinoma, renal papillary cell carcinoma, head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), ovarian cancer, ovarian carcinoma, ovarian serous cystadenocarcinoma, prostate cancer and/or prostate adenocarcinoma.

23. An antigen-binding molecule according to any one of claims **1** to **10**, a CAR according to claim **11**, a nucleic acid or a plurality of nucleic acids according to claim **12**, an expression vector or a plurality of expression vectors according to claim **13**, a cell according to claim **14**, or a composition according to claim **16** or claim **17**, for use in a method of treatment or prevention of a disease in which myeloid-derived suppressor cells (MDSCs) are pathologically implicated.

24. Use of an antigen-binding molecule according to any one of claims **1** to **10**, a CAR according to claim **11**, a nucleic acid or a plurality of nucleic acids according to claim **12**, an expression vector or a plurality of expression vectors according to claim **13**, a cell according to claim **14**, or a composition according to claim **16** or claim **17**, in the manufacture of a medicament for use in a method of treatment or prevention of a disease in which myeloid-derived suppressor cells (MDSCs) are pathologically implicated.

25. A method of treating or preventing a disease in which myeloid-derived suppressor cells (MDSCs) are pathologically implicated, comprising administering to a subject a therapeutically or prophylactically effective amount of an antigen-binding molecule according to any one of claims **1**